The literature produces some evidence of a higher early complication rate in obese patients undergoing THA, and operative time seems to be longer and blood loss greater than for matched controls. The only study looking at long-term outcome of THA showed no difference in hip survivorship at 10–18 years between obese and normal weight patients. We conclude that where THA is concerned, the PCT policy has no clinical or evidence based justification.